Literature DB >> 18841256

Comparison of one-year clinical outcomes with paclitaxel-eluting stents versus bare metal stents in everyday practice.

Mayraj Ahmad1, Jon-David R Schwalm, James L Velianou, Dan Pericak, Madhu K Natarajan.   

Abstract

BACKGROUND: In randomized trials, paclitaxel-eluting stents (PES) have been shown to be superior to bare metal stents (BMS) in reducing restenosis. However, the effectiveness of PES in patients treated during routine practice has not been fully established.
METHODS: A retrospective comparison of PES with BMS in consecutive patients undergoing percutaneous coronary intervention (PCI) from April 2003 to March 2004 was conducted. Outcomes included the composite of death, myocardial infarction and target lesion revascularization (TLR) at one year, as well as stent thrombosis.
RESULTS: A total of 512 patients were treated with PES, and 722 patients were treated with BMS. Patients in the PES group were more likely to receive stents that were 20 mm in length or longer (52.2% versus 33.3%, P<0.0001), 2.5 mm in diameter or smaller (29.1% versus 12.5%, P<0.0001) and implanted in bifurcation positions (15.4% versus 11.6%, P=0.02). At one year, the composite outcome of death, myocardial infarction and TLR was 6.1% in the PES group compared with 10.8% in the BMS group (P=0.004). The one-year rate of stent thrombosis was 0.59% in the PES group compared with 0.28% in the BMS group (P=0.4).
CONCLUSIONS: Despite being used in higher-risk lesions, there was a lower rate of major cardiac events at one year in patients treated with PES, primarily driven by the reduction in TLR. Thus, the experience with PES in contemporary practice applied to a broader population appears to be consistent with the results reported in randomized trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18841256      PMCID: PMC2643157          DOI: 10.1016/s0828-282x(08)70682-2

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  17 in total

1.  Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.

Authors:  D E Cutlip; D S Baim; K K Ho; J J Popma; A J Lansky; D J Cohen; J P Carrozza; M S Chauhan; O Rodriguez; R E Kuntz
Journal:  Circulation       Date:  2001-04-17       Impact factor: 29.690

2.  Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies.

Authors:  Raúl Moreno; Cristina Fernández; Rosana Hernández; Fernando Alfonso; Dominick J Angiolillo; Manel Sabaté; Javier Escaned; Camino Bañuelos; Antonio Fernández-Ortiz; Carlos Macaya
Journal:  J Am Coll Cardiol       Date:  2005-03-15       Impact factor: 24.094

3.  Primary and rescue percutaneous coronary intervention with paclitaxel-eluting stent implantation in ST-elevation myocardial infarction.

Authors:  Jon-David Reid Schwalm; Mayraj Ahmad; James L Velianou; Changchun Xie; Madhu K Natarajan
Journal:  Am J Cardiol       Date:  2006-03-20       Impact factor: 2.778

4.  Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials.

Authors:  Anthony A Bavry; Dharam J Kumbhani; Thomas J Helton; Przemyslaw P Borek; Girish R Mood; Deepak L Bhatt
Journal:  Am J Med       Date:  2006-12       Impact factor: 4.965

5.  The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry.

Authors:  Andrew T L Ong; Patrick W Serruys; Jiro Aoki; Angela Hoye; Carlos A G van Mieghem; Gaston A Rodriguez-Granillo; Marco Valgimigli; Karel Sonnenschein; Evelyn Regar; Martin van der Ent; Peter P T de Jaegere; Eugene P McFadden; Georgios Sianos; Willem J van der Giessen; Pim J de Feyter; Ron T van Domburg
Journal:  J Am Coll Cardiol       Date:  2005-04-05       Impact factor: 24.094

6.  Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme.

Authors: 
Journal:  Eur Heart J       Date:  2001-04       Impact factor: 29.983

7.  Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.

Authors:  Ioannis Iakovou; Thomas Schmidt; Erminio Bonizzoni; Lei Ge; Giuseppe M Sangiorgi; Goran Stankovic; Flavio Airoldi; Alaide Chieffo; Matteo Montorfano; Mauro Carlino; Iassen Michev; Nicola Corvaja; Carlo Briguori; Ulrich Gerckens; Eberhard Grube; Antonio Colombo
Journal:  JAMA       Date:  2005-05-04       Impact factor: 56.272

8.  One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.

Authors:  Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell
Journal:  Circulation       Date:  2004-04-12       Impact factor: 29.690

9.  Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.

Authors:  Philip Urban; Anthony H Gershlick; Giulio Guagliumi; Philippe Guyon; Chaim Lotan; Joachim Schofer; Ashok Seth; J Eduardo Sousa; William Wijns; Claude Berge; Monika Deme; Hans-Peter Stoll
Journal:  Circulation       Date:  2006-03-13       Impact factor: 29.690

Review 10.  Thrombosis and drug-eluting stents: a critical appraisal.

Authors:  Dean J Kereiakes; Joseph K Choo; John J Young; Thomas M Broderick
Journal:  Rev Cardiovasc Med       Date:  2004       Impact factor: 2.930

View more
  2 in total

1.  Long-term outcomes with paclitaxel-eluting stents versus bare metal stents in everyday practice: a Canadian experience.

Authors:  Jon-David R Schwalm; Mayraj Ahmad; James L Velianou; Dan Pericak; Madhu K Natarajan
Journal:  Can J Cardiol       Date:  2010-02       Impact factor: 5.223

2.  Delayed educational reminders for long-term medication adherence in ST-elevation myocardial infarction (DERLA-STEMI): protocol for a pragmatic, cluster-randomized controlled trial.

Authors:  Noah M Ivers; Jon-David Schwalm; Jeremy M Grimshaw; Holly Witteman; Monica Taljaard; Merrick Zwarenstein; Madhu K Natarajan
Journal:  Implement Sci       Date:  2012-06-09       Impact factor: 7.327

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.